DaVita Inc. (NYSE:DVA) Receives Consensus Recommendation of “Hold” from Analysts

Shares of DaVita Inc. (NYSE:DVA) have earned a consensus rating of “Hold” from the eight research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $199.1667.

A number of analysts have issued reports on the company. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Truist Financial raised their target price on DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a research report on Friday, May 8th. Deutsche Bank Aktiengesellschaft raised DaVita from a “hold” rating to a “buy” rating and upped their price target for the company from $126.00 to $220.00 in a report on Wednesday, May 6th. TD Cowen increased their price target on shares of DaVita from $144.00 to $201.00 and gave the company a “hold” rating in a research note on Monday. Finally, UBS Group raised their price objective on shares of DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a report on Thursday, May 7th.

DaVita Trading Up 3.6%

Shares of NYSE:DVA opened at $199.43 on Friday. DaVita has a 52 week low of $101.00 and a 52 week high of $202.69. The company’s 50 day moving average is $158.38 and its two-hundred day moving average is $135.58. The company has a market cap of $12.80 billion, a PE ratio of 18.50, a P/E/G ratio of 0.63 and a beta of 0.84.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. The firm had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The company’s revenue was up 6.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities research analysts expect that DaVita will post 15.07 EPS for the current year.

Insider Activity at DaVita

In related news, CFO Joel Ackerman sold 51,471 shares of DaVita stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the sale, the chief financial officer directly owned 132,434 shares in the company, valued at $25,440,571.40. This trade represents a 27.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On DaVita

Large investors have recently bought and sold shares of the stock. Root Financial Partners LLC increased its position in shares of DaVita by 128.0% during the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after purchasing an additional 105 shares in the last quarter. Elevation Wealth Partners LLC grew its stake in DaVita by 147.3% during the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock worth $31,000 after buying an additional 165 shares during the last quarter. Caitlin John LLC purchased a new position in DaVita during the 4th quarter worth approximately $34,000. Sankala Group LLC acquired a new position in DaVita during the fourth quarter worth approximately $39,000. Finally, Canada Pension Plan Investment Board purchased a new stake in DaVita in the second quarter valued at approximately $43,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.